8-K: VBI Vaccines Initiates Restructuring Proceedings Under CCAA, Seeks DIP Financing

VBI Vaccines has commenced voluntary restructuring under the Companies' Creditors Arrangement Act (CCAA) in Canada, along with related proceedings in the U.S. and Israel, and secured debtor-in-possession financing.

Summary

• VBI Vaccines Inc. has initiated voluntary restructuring proceedings under the Companies' Creditors Arrangement Act (CCAA) in Canada.
• The company also intends to commence proceedings under Chapter 15 of the U.S. Bankruptcy Code and the Israeli Insolvency and Economic Rehabilitation Law.
• These actions are collectively referred to as the Restructuring Proceedings.
• The Ontario Superior Court of Justice has granted an initial order providing a stay of proceedings in favor of VBI.
• Ernst & Young Inc. (EY) has been appointed as monitor during the Restructuring Proceedings.
• VBI has secured a Debtor-in-Possession (DIP) financing facility of up to $2.5 million from K2 HealthVentures LLC.
• The DIP facility has an interest rate of 17.5% per annum and matures on the earliest of several conditions, including September 6, 2024.
• The company expects its common shares to cease trading on the Nasdaq Capital Market and to cease reporting as a public company.
• The restructuring is intended to allow VBI to review strategic alternatives, including a potential sale of assets.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event with the company initiating restructuring proceedings and facing delisting. The high interest rate on the DIP financing and the default on the loan agreement further contribute to the negative sentiment.

Positives

• The company has secured DIP financing to fund operations during the restructuring process.
• The CCAA proceedings provide a stay of proceedings, protecting the company from creditors while it explores strategic alternatives.
• The company intends to conduct a sale and investment solicitation process (SISP) to explore strategic alternatives.

Negatives

• The company has initiated restructuring proceedings, indicating significant financial distress.
• The DIP financing comes with a high interest rate of 17.5% per annum.
• The company's shares are expected to be delisted from the Nasdaq Capital Market.
• The company expects to cease reporting as a public company.
• The commencement of restructuring proceedings triggered an event of default under the Loan Agreement, making all obligations immediately due and payable.

Risks

• Trading in the company's securities during the restructuring is highly speculative and poses substantial risks.
• The company's ability to successfully complete a sale process is uncertain.
• There are risks associated with employee attrition and the ability to retain key personnel during the restructuring.
• The company faces potential adverse effects on its liquidity and results of operations due to the restructuring.
• There are risks associated with third-party motions that could interfere with the company's ability to consummate a sale.
• The company faces increased administrative and legal costs related to the restructuring proceedings.

Future Outlook

The company intends to conduct a sale and investment solicitation process (SISP) to explore strategic alternatives, including a potential sale of assets. The company expects to cease trading on Nasdaq and cease reporting as a public company.

Management Comments

• The decision to seek creditor protection was made in the best interest of its stakeholders after careful evaluation of VBI's financial situation and all available alternatives.
• The board of directors of VBI will remain in place and VBI will remain responsible for the sale process under the supervision of the CCAA Court and the general oversight of the Monitor.

Industry Context

The biopharmaceutical industry is capital intensive and companies in the development stage often face financial challenges. VBI's restructuring highlights the risks associated with drug development and the need for strong financial management. This situation is not uncommon in the biotech sector, where companies can face difficulties in securing funding and achieving commercial success.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face financial difficulties and may need to restructure or seek bankruptcy protection.
• The DIP financing secured by VBI is a common mechanism for companies undergoing restructuring to maintain operations.
• The high interest rate on the DIP facility is typical for distressed financing situations.
• The delisting of shares from Nasdaq is a common consequence of bankruptcy or restructuring proceedings.
• The use of CCAA and Chapter 15 proceedings is a standard approach for companies with international operations seeking creditor protection.

Legal Proceedings

• The company has commenced voluntary restructuring under the jurisdiction of the Ontario Superior Court of Justice (Commercial List) pursuant to the Companies Creditors Arrangement Act (the CCAA Proceedings).
• The company intends to commence a case under Chapter 15 of the United States Bankruptcy Code (the Bankruptcy Code) under the jurisdiction of the U.S. Bankruptcy Court for the District of Delaware (the Chapter 15 Proceedings).
• The company intends to commence proceedings under the relevant provisions of the Israeli Insolvency and Economic Rehabilitation Law, 2018 (the Israeli Proceedings).

Stakeholder Impact

• Shareholders face significant risks and potential loss of investment due to the restructuring and delisting.
• Employees face uncertainty regarding their jobs and compensation during the restructuring.
• Creditors are subject to a stay of proceedings and may face losses.
• Customers and suppliers may experience disruptions due to the restructuring.

Next Steps

• The company will proceed with the CCAA proceedings in Canada.
• The company will commence Chapter 15 proceedings in the U.S.
• The company will commence proceedings under the Israeli Insolvency Law.
• The company will seek approval for a sale and investment solicitation process (SISP).
• The company will use the DIP financing to fund operations during the restructuring.

Key Dates

Keywords

restructuring, CCAA, Chapter 15, DIP financing, bankruptcy, delisting, sale process, insolvency, K2 HealthVentures, Ernst & Young